Jim Rock, VP Clinical Operations and Research Contracts at DermTech, says, "As the power of our gene expression technology becomes more transparent to the industry, additional biopharmaceutical companies are approaching us to assist in early-stage clinical development of their technologies. These two recent collaborations are further examples of our value add proposition and leadership in molecular dermatology."
Rock adds, "We continue to focus on offering the newest gene expression technology to enhance the understanding of treatment effects and response rates in target populations with new drugs and treatments, providing an invaluable tool in biopharmaceutical drug development."
As the global leader in molecular dermatology, DermTech markets and develops non-invasive gene expression tests to aid the clinical diagnosis of skin cancer, assess inflammatory diseases, and personalize drug treatment. DermTech's technology allows for the analysis of skin biopsy samples that are collected non-invasively using an adhesive patch.